Inogen, Inc.
NASDAQ:INGNMedical - Devices
+$0.05 today
- Market cap
- $144.83M
- Beta
- 1.59
- P/E (TTM)
- -7.0
- EPS (TTM)
- -$0.91
Volume 0.19M
Average 0.33M
INGN Capital Expenditures
Cash spent on property, plant, equipment, and other long-term assets.
Inogen, Inc.NASDAQ: INGN
Capital Expenditures · Q1 FY2026 · quarter ended Mar 2026
Capital expenditures declines year over year
Q1 FY2026 capital expenditures of $781K (cash outflow) fell 61.7% year over year, behind the -39.2% change in trailing-twelve-month capital expenditures. Sequentially, it fell 67.1% from the prior quarter. Over 3 fiscal years it compounded at -21.2% a year.
Context
- Capital expenditures amounted to 3.0% of revenue in FY2025, down 2.1 pp from a year earlier.
- Capital expenditures grew in size in 1 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -61.7% toward the trailing-twelve-month pace of -39.2%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Capital Expenditures history
USD · from the cash flow
- Latest · FY2025
- (10.38M) USD
- Year-over-year change
- +39.3%
| Period | Period end | Capital Expenditures | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (10.38M) | +39.3% |
| FY2024 | 2024-12-31 | (17.09M) | +35.5% |
| FY2023 | 2023-12-31 | (26.52M) | -25.0% |
| FY2022 | 2022-12-31 | (21.22M) | +11.3% |
| FY2021 | 2021-12-31 | (23.94M) | — |
Capital Expenditures vs competitors
How INGN compares with its peers on the latest reported figures
- INGN's LTM Mar 2026 capital expenditures of $9.13M is the 4th largest of the 11 companies compared; the peer median is $1.09M.
- Its year-over-year change of -39.2% is the 7th highest of 9, against a peer median of +7.3%.
- Capital expenditures amounts to 2.6% of revenue for INGN, versus a peer median of 1.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $14.95M | -70.1% | +248.2% | 2419.3% | |
| LTM Mar 2026 | $9.79M | -31.3% | -61.8% | 3.2% | |
| LTM Mar 2026 | $9.3M | — | — | 17.3% | |
| LTM Mar 2026 | $9.13M | -39.2% | -21.2% | 2.6% | |
| LTM Dec 2025 | $4.45M | +61.0% | -16.3% | 34.2% | |
| LTM Mar 2026 | $1.44M | -65.0% | -39.4% | 1.0% | |
| LTM Mar 2026 | $740K | +8.7% | -54.2% | 0.6% | |
EPRXEupraxia Pharmaceuticals Inc. | LTM Mar 2026 | $728.23K | +188.5% | +36.5% | — |
| LTM Mar 2026 | $284K | +6.0% | -38.6% | 0.4% | |
| LTM Mar 2026 | $73K | +113.6% | — | 0.2% | |
| LTM Mar 2026 | $0 | — | +1281.0% | 0.0% | |
| Peer median (excluding INGN) | $1.09M | +7.3% | -27.5% | 1.0% | |
Competitors are the stored peer set for INGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (6.33M) | (83.77M) | (102.45M) | (35.89M) | (22.75M) |
| Depreciation & Amortization | 21.63M | 23.51M | 18.15M | 21M | 20.66M |
| Deferred Income Tax | 14.44M | 0 | (251K) | (1.15M) | (1.1M) |
| Stock-Based Compensation | 10.94M | 12.28M | 7.43M | 7.4M | 8.01M |
| Change in Working Capital | (20.07M) | (44.72M) | 14.27M | (4.39M) | (26.91M) |
| Accounts Receivables | (5.42M) | (51.62M) | 11.13M | (5.07M) | (14.62M) |
| Inventory | (10.78M) | (5.6M) | 7.88M | (3.54M) | (3.21M) |
| Accounts Payables | (6.48M) | 6.76M | (9.18M) | (3.41M) | 5.6M |
| Other Working Capital | 2.61M | 5.74M | 4.44M | 7.63M | (14.68M) |
| Other Non-Cash Items | 3.02M | 55.16M | 59.62M | 18.94M | 10.87M |
| Operating Cash Flow | 23.63M | (37.53M) | (3.23M) | 5.91M | (11.22M) |
| Capital Expenditures | (23.94M) | (21.22M) | (26.52M) | (17.09M) | (10.38M) |
| Acquisitions (Net) | 153K | 331K | (29.44M) | 0 | 0 |
| Purchases of Investments | (9.99M) | 0 | (26.87M) | (32.66M) | (29.83M) |
| Sales of Investments | 19.26M | 10.01M | 24M | 35.5M | 14M |
| Other Investing Activities | 0 | 0 | 0 | (1.82M) | 0 |
| Investing Cash Flow | (14.65M) | (10.88M) | (59.32M) | (13.98M) | (26.21M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 15.65M | 1.74M | 1.48M | 811K | 28.18M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (647K) | (1.36M) | (518K) | (546K) | (4M) |
| Financing Cash Flow | 15M | 380K | 960K | 265K | 24.18M |
| Effect of Forex Changes | (426K) | (481K) | 67K | (281K) | 846K |
| Net Change in Cash | 23.56M | (48.51M) | (61.52M) | (8.08M) | (12.4M) |
| Free Cash Flow | (302K) | (58.75M) | (29.75M) | (11.18M) | (21.6M) |
Inogen, Inc.
NASDAQ:INGN
Intrinsic Alpha fair value
Locked
Current Price
$5.57
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.